Ropeginterferon alfa-2b not checked
PharmaEssentia · P1101
FollowEvery change as it happens, and a Monday email
Trials
8 active
16 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- Interferon alfa-2b FDA class
- How it’s given
- “Ropeginterferon alfa-2b (P1101) dosage: from 250 mcg to 500 mcg”In the company’s words, NCT04285086 on ClinicalTrials.gov
- Tested for
- Essential Thrombocythemia (2 trials), Polycythemia Vera (2 trials), Polycythemia Vera (PV), Primary Myelofibrosis, Myeloproliferative Neoplasm
- Main trialPhase 3
- “This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.”In the company’s words, NCT04285086 on ClinicalTrials.gov
- Other names
- P1101 · BESREMI
- Copy of
- Pegintron (Schering)Tested side by side with the original in NCT04382937
- Given with
- Pegasys (Pharmaand Gmbh)Other companies’ drugs in its trials
Other drugs for Essential Thrombocythemia
- BomedemstatMerck & Co. · Phase 3
- Pegylated-Proline-interferon alpha-2bAOP Orphan Pharmaceuticals AG · Phase 3
- INCA033989Incyte Corporation · Phase 3
- Givinostat HydrochlorideItalfarmaco · Phase 2
- STP938Step Pharma, SAS · Phase 2
- JBI-802Jubilant Therapeutics Inc. · Phase 1/2
Coming up1
- 18 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 12 Nov 2024 | Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | |
| Phase 3Active, not recruiting | 30 Jun 2025 | A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV | |
| Phase 3Recruiting | 30 Jun 2026 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | |
| Phase 3Active, not recruiting | 18 Nov 2027 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | |
| Phase 2Active, not recruiting | 7 Sep 2022 | A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | |
| Phase 2Active, not recruiting | 9 May 2025 | A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET | |
| Phase 4Withdrawn | 31 Dec 2026 | Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera | |
| Phase 3Completed | 15 Jul 2020 | Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection | |
| Phase 3Completed | 26 Jul 2024 | A Study to Evaluate P1101 in Japanese PV Patients | |
| Phase 2Completed | 22 Nov 2016 | Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection | |
| Phase 2Completed | 8 Mar 2021 | Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply | |
| Phase 1Completed | 26 Jun 2010 | Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects | |
| Phase 1Completed | 18 Jul 2022 | The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection | |
| Phase 1Completed | 8 Apr 2026 | The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection | |
| Phase 3Authorised | not given | A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments | |
| Phase 2Authorised | not given | A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL (BosuPeg) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026